|
|
||||||||
2004 CARDIOVASCULAR AND KIDNEY INVESTIGATORS MEETING
Division of Cardiology, Department of Medicine, Emory University, Atlanta, Georgia
Submitted 26 June 2004 ; accepted in final form 25 August 2004
| ABSTRACT |
|---|
|
|
|---|
reactive oxygen species; oxidant signaling; hypertrophy; vascular smooth muscle cells
Angiotensin II (ANG II) is a well-established and potent mediator of disease-related vascular wall remodeling, an integral part of which is VSMC hypertrophy (17). ANG II regulates the activity of VSMC NAD(P)H oxidases on at least two levels. Not only are NAD(P)H oxidases activated acutely via phosphorylation cascades (19), but also long-term treatment of rodents with ANG II leads to an upregulation of p22phox and its catalytic subunits Nox1 and Nox4 (2, 14). Wang et al. (22) have shown that ANG II-induced hypertrophy is decreased in gp91phox/ mice, implicating NAD(P)H oxidases in the hypertrophic response to ANG II. However, the role of media-derived ROS remains unclear.
Because oxidant stress is so closely related to vascular pathology, it has been difficult to study the effect of chronic elevation in ROS in the absence of other disease-promoting stimuli. Excessive ROS may be sufficient to initiate disease progression or they may be harmful only in the context of other pathogenic events. In the current study, we used mice that overexpress p22phox exclusively in smooth muscle [Tgp22smc (11)] to investigate the role of smooth muscle oxidases in vascular hypertrophy. We found that increasing ROS production in the media has little effect by itself but clearly potentiates the hypertrophic response to ANG II. These findings indicate that elevated NAD(P)H oxidase expression in pathologies such as hypertension or atherosclerosis may contribute significantly to abnormal vascular growth and remodeling.
| MATERIALS AND METHODS |
|---|
|
|
|---|
-actin promoter fragment SMP-8 and upstream of a SV40 poly A fragment. The construct was linearized and injected into eggs, and mice were screened for insertion of p22phox. Founder mice were then backcrossed 10 generations to the C57BL/6J strain. For the current experiments, mice that were heterozygous for p22phox overexpression in smooth muscle (Tgp22smc) and their negative littermate controls were used. Genotyping was determined using polymerase chain reaction by amplifying the SV40 promoter (a unique sequence found only following insertion of the transgene). Studies were completed in adult male mice, ages 1218 wk. All animal experiments were approved by the Emory University Animal Care and Use Committee. Infusion protocols. Mice were anesthetized, and osmotic pumps containing 100 µl of either saline or ANG II (Sigma; St. Louis, MO) were implanted subcutaneously. ANG II was administered at a dose of 0.7 mg·kg1·day1. During infusion, blood pressure was determined using standard tail-cuff methods (Visitech; Apex, NC). Additional groups of control and Tgp22smc mice were coinfused with ebselen (Cayman Chemical; Ann Arbor, MI) dissolved in 50% DMSO administered at a dose of 10 mg·kg1·day1 via a second osmotic pump. Control mice received 50% DMSO alone. It should be noted that in vivo, ebselen exists mainly as the thiol-bound form, of which the primary cellular action is as a glutathione peroxidase mimetic. However, ebselen can also inhibit other sources of ROS, such as lipoxygenases, protein kinase C, and NAD(P)H oxidases (18).
Western blotting analysis and immunofluorescence. For both procedures, animals were euthanized by CO2 inhalation after the infusion protocol was completed. Aortas were carefully excised, and adventitia was removed. For Western blot analysis, tissues were minced, proteins were extracted, and Western blot analysis was completed as described previously (16). Membranes were incubated with a mouse monoclonal antibody that recognizes p22phox or a rabbit polyclonal antibody that recognizes Nox1 (a kind gift of Dr. H. Schmidt). The mouse monoclonal p22phox antibody was raised against a GST-p22phox fusion protein. It recognizes p22phox purified from baculovirus but does not recognize GST.
Immunofluorescence was assessed using 7-µm OCT-embedded tissue sections fixed in acetone. After incubation in blocking buffer [3% bovine serum albumin (BSA) in phosphate-buffered saline (PBS)] for 1 h, sections were incubated with rabbit polyclonal p22phox antibody (a kind gift of Dr. Mark Quinn) (1:100 dilution in 1.0% BSA in PBS for 1 h), washed, and incubated with secondary antibody conjugated to rhodamine red for 30 min. Serial sections treated with secondary antibodies alone confirmed that fluorescence was not due to nonspecific binding. Aortas from a minimum of three animals per group were stained for p22phox expression. Digital images of the sections were obtained using a Zeiss Axioskop.
Measurement of H2O2. After the infusion protocol, mice were euthanized by CO2 inhalation. Aortas were excised, and adherent fat was removed. H2O2 was measured using a fluorometric horseradish peroxidase-linked assay (Amplex red assay, Molecular Probes) (24). This assay has been reported to be capable of detecting low levels of H2O2 production and is specific for measuring H2O2 generation because the fluorescence is inhibitable by catalase (12). Briefly, aortic segments (5-mm rings) were incubated with Amplex red (100 µM) and horseradish peroxidase (1 U/ml) for 30 min at 37°C in Krebs-HEPES buffer protected from light. Fluorescence was measured (excitation 530 nm, detection 590 nm), and background fluorescence, determined in a control reaction without sample, was subtracted from each value. H2O2 release was calculated using H2O2 standards and expressed as picomoles per milligram of dry tissue.
Morphometric analysis. After the animal was euthanasized, the heart and aorta were pressure perfused at 100 mmHg with 0.9% sodium chloride solution, followed by pressure fixation with a 10% formalin solution. Aortas were embedded in paraffin, cut in 5-µm cross sections, and stained with hematoxylin and eosin. Scaled digital images were obtained using a Zeiss Axioskop. To quantify wall thickness, perpendicular lines were drawn to determine the distance from internal elastic lamina to the external lamina at a minimum of eight locations of the aortic section. To determine cross-sectional wall area, the perimeters of the internal and external elastic laminas were traced. The area inside each respective perimeter was determined, and the difference between these areas was reported as the aortic wall area. All measurements were completed using National Institutes of Health Image (version 1.62), and analysis of subsequent sections from each animal validated the consistency of the quantification techniques.
Statistical analysis. Results are expressed as means ± SE. Statistical significance, assessed by ANOVA with Newman-Keuls multiple comparison posttest, was performed using GraphPad Prism software. A value of P < 0.05 was considered to be statistically significant.
| RESULTS |
|---|
|
|
|---|
|
In accord with the increased expression of these NAD(P)H oxidase proteins, Tgp22smc mice also demonstrate a twofold increase in basal H2O2 production compared with C57BL/6J mice (Fig. 2). ANG II infusion further potentiated the increase in H2O2 production in Tgp22smc mice compared with its effect in wild-type mice. Infusion of the glutathione peroxidase mimetic ebselen induced a small, nonsignificant increase in H2O2 production in saline-infused mice but had no effect on basal H2O2 production in Tgp22smc mice. As expected, ebselen prevented the exacerbated H2O2 production in response to ANG II in Tgp22smc mice.
|
|
p22phox overexpression potentiates aortic hypertrophy. It has been reported in vitro that p22phox antisense treatment inhibits ROS production in response to ANG II and that this inhibition prevents ANG II-induced hypertrophy in cultured VSMC (21). However, the phenotypic modulation that occurs in culture raises the question of whether p22phox-containing NAD(P)H oxidases have a similar role in vivo. To test this notion, we assessed aortic hypertrophy after 13 days of ANG II infusion in Tgp22smc mice. After saline infusion for 13 days, cross sections from C57BL/6J and Tgp22smc mice appear similar (Fig. 3, A and C), suggesting that the basal changes in these mice do not significantly affect vascular growth. Similar to previous reports in both rats and mice (1, 22), ANG II infusion leads to significant hypertrophy of the aorta in both C57BL/6J and Tgp22smc mice compared with mice receiving saline (Fig. 3, B and D). Interestingly, aortic hypertrophy in response to ANG II infusion was significantly increased in Tgp22smc mice relative to C57BL/6J mice receiving ANG II, suggesting that the increased ROS generation in Tgp22smc mice potentiated vascular growth in vivo.
|
|
|
| DISCUSSION |
|---|
|
|
|---|
p22phox alone does not support superoxide production but has been clearly shown to stabilize the expression of gp91phox(6) and Nox1 (7) in culture. Our data indicate that p22phox overexpression in mice concomitantly upregulates Nox1, consistent with such an effect in vivo. We and others (2, 14) have previously shown that ANG II increases aortic p22phox and Nox1 expression, similar to the results shown here (Fig. 1A). It is of interest that ANG II further increases p22phox expression in Tgp22smc mice, perhaps because the smooth muscle
-actin promoter, from which SMP-8 is derived, is responsive to ANG II (8). Despite the large increase in p22phox expression after ANG II, Nox1 levels were only slightly increased over basal levels in these mice, suggesting that the regulation of Nox1 by ANG II involves more that merely costabilization by p22phox. The increase in Nox1 and p22phox appears to result in enhanced oxidase activity, because the H2O2 response to ANG II is increased in Tgp22smc mice (Fig. 2).
This increase in ROS in Tgp22smc mice is associated with an enhanced hypertrophic response to ANG II, consistent with our previous in vitro findings (23). The ability of ebselen to block the exacerbated hypertrophy in Tgp22smc mice strongly suggests that this effect is due to ROS. It is worth noting, however, that Tgp22smc mice exhibit not only an increase in vascular ROS production but also an increase in eNOS expression and endothelial NO production (11). NO is known to inhibit vascular smooth muscle growth (3), suggesting that aortic hypertrophy in the Tgp22smc mice might have been greater in the absence of this compensatory response. It is surprising that in C57BL/6J mice, ANG II did not increase H2O2 levels and that vascular hypertrophy is not blocked by ebselen coinfusion. There are several possible explanations for this observation. First, we only measured H2O2 at 13 days after ANG II infusion, and it is possible that H2O2 production may indeed be increased at earlier times. Arguing against this possibility is the observation that ebselen did not block hypertrophy in wild-type mice. Second, it is possible that ROS are not normally involved in ANG II-induced hypertrophy. This is unlikely, however, given the strong evidence of a requirement for NAD(P)H oxidases in ANG II-induced vascular growth both in vitro (4, 21, 23) and in vivo (22). Third, although ebselen reduces H2O2 levels, it does not target other ROS such as superoxide, which may also play a role in vascular growth (20). Finally, ebselen, at the concentrations used here, does not reduce H2O2 levels to baseline, suggesting that perhaps in wild-type mice the amount of H2O2 produced by ANG II is sufficient to support hypertrophy even in the presence of ebselen.
Another consideration in comparing the hypertrophic response in wild-type and Tgp22smc mice is that the blood pressure response is higher in the transgenic mice, at least up to day 9. The increased blood pressure in the transgenic animals is presumably due to enhanced inactivation of nitric oxide by superoxide, however, so that even this potential effect of pressure on hypertrophy is ROS dependent. Indeed, analysis of pressure versus wall thickness or wall area in all animals in this study shows a strong correlation between these two factors (r = 0.78 for wall thickness and r = 0.85 for wall area). Furthermore, by day 13, the blood pressures are no longer different between the two strains, suggesting that the induced changes in wall thickness have successfully compensated for the increased pressure. Arguing against this interpretation, however, is the observation that even though ebselen was able to prevent exacerbation of ANG II-induced H2O2 production and hypertrophy in Tgp22phox mice (Figs. 4 and 5), these mice still had elevated blood pressure, although this increase was less than in mice receiving ANG II alone (Table 1). Taken together, these considerations suggest that it is unlikely that either ROS or blood pressure is acting exclusively to facilitate the vascular hypertrophy in the Tgp22smc mice.
These studies clearly demonstrate that alteration of medial redox status can influence vascular hypertrophy. Previous work has shown that production of ROS by either the endothelium or adventitia can alter medial hypertrophy (22). Each layer of the vessel wall has a different complement of NAD(P)H oxidases, which in turn is differentially regulated (9). This permits exquisitely fine control of ROS production both in terms of hormonal control and spatial responsiveness. The interplay between the gp91phox-based NAD(P)H oxidases in the adventitia and the Nox1 or Nox4-based oxidases in the media may be of vital importance to the pathogenesis of vascular disease.
In summary, Tgp22smc mice represent an excellent model with which to study the effect of NAD(P)H oxidase upregulation in the media. NAD(P)H oxidase expression is increased following balloon injury, in various hypertensive models, and in the shoulder of the atherosclerotic plaque (9). All of these pathologies are accompanied by multiple other triggers of vascular disease, including increases in inflammatory mediators and cytokines. In this study, we found that long-term medial oxidant stress is by itself insufficient to trigger vascular remodeling. However, in the presence of the inflammatory and hypertensive stimulus ANG II, upregulation of medial NAD(P)H oxidases plays an important role in disease initiation and progression. Our results clearly show that increased availability of NAD(P)H oxidase-derived ROS in the media potentiates ANG II-induced vascular hypertrophy, making ROS an excellent target for intervention aimed at reducing medial thickening in vivo.
| ACKNOWLEDGMENTS |
|---|
| FOOTNOTES |
|---|
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
| REFERENCES |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
Y. Wang and M. F. Lou The Regulation of NADPH Oxidase and Its Association with Cell Proliferation in Human Lens Epithelial Cells Invest. Ophthalmol. Vis. Sci., May 1, 2009; 50(5): 2291 - 2300. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M. Beyer, W. J. de Lange, C. M. Halabi, M. L. Modrick, H. L. Keen, F. M. Faraci, and C. D. Sigmund Endothelium-Specific Interference With Peroxisome Proliferator Activated Receptor Gamma Causes Cerebral Vascular Dysfunction in Response to a High-Fat Diet Circ. Res., September 12, 2008; 103(6): 654 - 661. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. K. Doughan, D. G. Harrison, and S. I. Dikalov Molecular Mechanisms of Angiotensin II-Mediated Mitochondrial Dysfunction: Linking Mitochondrial Oxidative Damage and Vascular Endothelial Dysfunction Circ. Res., February 29, 2008; 102(4): 488 - 496. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Dikalov, K. K. Griendling, and D. G. Harrison Measurement of Reactive Oxygen Species in Cardiovascular Studies Hypertension, April 1, 2007; 49(4): 717 - 727. [Full Text] [PDF] |
||||
![]() |
M. C. Gongora, Z. Qin, K. Laude, H. W. Kim, L. McCann, J. R. Folz, S. Dikalov, T. Fukai, and D. G. Harrison Role of Extracellular Superoxide Dismutase in Hypertension Hypertension, September 1, 2006; 48(3): 473 - 481. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. N. Lyle and K. K. Griendling Modulation of vascular smooth muscle signaling by reactive oxygen species. Physiology, August 1, 2006; 21: 269 - 280. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. S. Wilcox Oxidative stress and nitric oxide deficiency in the kidney: a critical link to hypertension? Am J Physiol Regulatory Integrative Comp Physiol, October 1, 2005; 289(4): R913 - R935. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Cai Hydrogen peroxide regulation of endothelial function: Origins, mechanisms, and consequences Cardiovasc Res, October 1, 2005; 68(1): 26 - 36. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. S. Wilcox and D. Gutterman Focus on oxidative stress in the cardiovascular and renal systems Am J Physiol Heart Circ Physiol, January 1, 2005; 288(1): H3 - H6. [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |